Medpace Holdings, Inc.

NasdaqGS:MEDP Lagerbericht

Marktkapitalisierung: US$12.0b

Medpace Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Medpace Holdings wird ein jährliches Gewinn- und Umsatzwachstum von 9.4% bzw. 7.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 8.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 33% betragen.

Wichtige Informationen

9.4%

Wachstumsrate der Gewinne

8.68%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum17.5%
Wachstumsrate der Einnahmen7.5%
Zukünftige Eigenkapitalrendite33.04%
Analystenabdeckung

Good

Zuletzt aktualisiert27 Apr 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Analyseartikel • Apr 26

Medpace Holdings, Inc. Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

Shareholders in Medpace Holdings, Inc. ( NASDAQ:MEDP ) had a terrible week, as shares crashed 21% to US$411 in the week...
Analyseartikel • Feb 13

Medpace Holdings, Inc. (NASDAQ:MEDP) Just Reported, And Analysts Assigned A US$491 Price Target

Shareholders in Medpace Holdings, Inc. ( NASDAQ:MEDP ) had a terrible week, as shares crashed 23% to US$416 in the week...

Recent updates

Narrativ-Update • May 14

MEDP: Slower Long Term Revenue Assumptions Will Challenge Rich P E Multiple

Medpace Holdings' fair value estimate has been trimmed by about $7 to $349.93 as analysts moderate long term revenue growth assumptions, while still recognizing higher profit margins and a slightly higher forward P/E in their updated price targets. Analyst Commentary Recent Street research on Medpace highlights a mix of cautious and constructive views, with several firms revising price targets and ratings as they reassess growth assumptions, margins, and sector trends in clinical research outsourcing.
Narrativ-Update • Apr 29

MEDP: Biotech Trial Efficiency And AI Savings Will Support Future Margin Resilience

Medpace Holdings' analyst price target has been reset from about $582 to roughly $495 as analysts factor in updated assumptions for revenue growth, margins and future P/E multiples, while still pointing to company specific strengths highlighted in recent research coverage and upgrades. Analyst Commentary Street research around Medpace has recently centered on recalibrating price targets while still emphasizing company specific strengths.
Analyseartikel • Apr 26

Medpace Holdings, Inc. Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

Shareholders in Medpace Holdings, Inc. ( NASDAQ:MEDP ) had a terrible week, as shares crashed 21% to US$411 in the week...
Seeking Alpha • Apr 24

Medpace Holdings: Downgrade To 'Buy' As Revenue Growth Remains, But With Caution Ahead

Summary Medpace Holdings is downgraded from 'Strong Buy' to 'Buy' due to rising backlog cancellations and elevated direct costs, despite robust revenue growth. MEDP delivered Q1 2026 revenue of $706.6M (+26.5% YoY) and beat both top- and bottom-line expectations, with strong Net New Business Awards growth. The Net Book-to-Bill ratio fell to 0.88x in Q1 2026, driven by the highest backlog cancellations in over a year, warranting caution. Full-year 2026 revenue guidance is raised to $2.755B–$2.855B, but persistent cancellation and cost risks could prompt further rating downgrades. Read the full article on Seeking Alpha
Narrativ-Update • Apr 15

MEDP: Slower Revenue Assumptions Will Test Rich Multiple And 2026 Execution

Medpace Holdings' analyst-derived fair value has inched up by about $5 to roughly $357, as analysts weigh higher assumed profit margins and a richer future P/E against slower projected revenue growth and a slightly higher discount rate, while incorporating a wave of recent rating upgrades and higher price targets clustered around $419 to $522. Analyst Commentary Recent research on Medpace reflects a mix of upgrades and cautious fine tuning, with several firms lifting ratings while keeping a close eye on valuation, end market trends, and execution risk.
Narrativ-Update • Apr 01

MEDP: Efficient Biotech Contracts And Buybacks Will Support Elevated Market Expectations

Analysts have inched up their blended price target on Medpace Holdings to about $500 per share from roughly $490, citing the company’s efficiency in contract research, ongoing biotech-focused wins, and a series of recent rating upgrades as key reasons for this recalibration. Analyst Commentary Recent research remains broadly constructive on Medpace, with several firms adjusting ratings and price targets as they reassess valuation, execution, and exposure to biotech customers.
Narrativ-Update • Mar 18

MEDP: Biotech Trial Efficiency And AI Savings Will Support Future Margin Strength

Analysts have nudged their overall price expectations for Medpace modestly higher, reflected in a slightly lower discount rate of 7.78% and small upward tweaks to revenue growth and profit margin assumptions. These changes are supported by a series of recent rating upgrades and fresh price targets in the $419 to $660 range.
Narrativ-Update • Mar 03

MEDP: Efficiency And Biotech Exposure Will Support Margin Strength Going Forward

Analysts have lifted their implied fair value estimate for Medpace Holdings to $582 from $510, citing the company's efficiency as a contract research organization, stronger profit margin assumptions at 17.94%, and a higher future P/E of about 29.35x as key supports for the updated price targets across recent research. Analyst Commentary Recent research coverage has highlighted a generally constructive tone around Medpace, with several bullish analysts pointing to efficiency, exposure to biopharma clients, and margin profile as key parts of the equity story.
Narrativ-Update • Feb 17

MEDP: Higher Margins And Buybacks Will Support Rich Market Expectations

Analysts have trimmed their average price target on Medpace Holdings by about $55 to $490.50 as revised models reflect updated revenue growth assumptions, a slightly different discount rate, higher expected profit margins, and a higher future P/E multiple, informed by a mix of recent upgrades and target changes across the Street. Analyst Commentary Recent research has produced a mix of upgrades and target cuts, with Street views clustering around how sustainable Medpace Holdings' growth, margins, and valuation may be after the latest earnings move.
Analyseartikel • Feb 13

Medpace Holdings, Inc. (NASDAQ:MEDP) Just Reported, And Analysts Assigned A US$491 Price Target

Shareholders in Medpace Holdings, Inc. ( NASDAQ:MEDP ) had a terrible week, as shares crashed 23% to US$416 in the week...
Narrativ-Update • Feb 03

MEDP: Decelerating Healthcare Utilization Will Test Rich Multiple And 2026 Execution

Analysts have nudged their price target for Medpace Holdings slightly higher, to $660 from $655, citing updated Q4 healthcare utilization survey findings and modest tweaks to growth, margin and future P/E assumptions in their models. Analyst Commentary Recent research around Medpace focuses on how healthcare utilization trends could influence growth expectations, margins and the valuation investors are willing to pay.
Narrativ-Update • Jan 20

MEDP: Biotech Recovery And Backlog Strength Will Challenge Rich Market Expectations

Narrative Update: Medpace Holdings Analyst Price Target Shift The updated analyst framework edges fair value for Medpace Holdings slightly higher to about $545.75 from roughly $541.92. This reflects modest tweaks to discount rate, growth, margin and P/E assumptions as analysts respond to a series of recent price target increases across the Street.
Narrativ-Update • Jan 06

MEDP: Rich Multiple Will Depend On Unproven 2026 Execution

Analysts raised their fair value estimate for Medpace Holdings from about $305 to roughly $356 per share, citing higher assumed revenue growth, slightly improved profit margins, and a modestly higher future P/E multiple in line with recent Street price target increases. Analyst Commentary Recent Street research on Medpace highlights a mix of optimism on the long term setup and caution around how much upside is already reflected in the current share price.
Narrativ-Update • Dec 21

MEDP: Biotech Funding Recovery And Backlog Trends Will Shape Future Prospects

Analysts have nudged their blended fair value estimate for Medpace Holdings slightly higher, to approximately $542 from $539, citing increased confidence in the durability of biotech recovery, a healthier pre-backlog pipeline, and signs that contract research trends have stabilized. Analyst Commentary Street research updates over the last several weeks reflect a generally constructive stance on Medpace, with multiple firms raising price targets while maintaining a range of ratings from Sell to Outperform.
Narrativ-Update • Dec 07

MEDP: Biotech Funding Recovery And Book-To-Bill Trends Will Shape Future Outlook

Analysts have nudged their price target on Medpace Holdings modestly higher by about $2 per share to reflect increased confidence in a sustained recovery in biotech funding, healthier book to bill trends, and signs that contract research organization demand has likely stabilized. Analyst Commentary Recent Street research reflects a more constructive stance on Medpace, with several bullish analysts lifting price targets to account for stronger sector fundamentals and improved visibility into the company’s growth trajectory.
Narrativ-Update • Nov 22

MEDP: Improving Biotech Pipeline And Book-To-Bill Trends Will Support Recovery Momentum

The analyst price target for Medpace Holdings has increased from $519 to $538. Analysts cite improving Biotech market confidence and stronger forward earnings projections as factors supporting this upward revision.
Narrativ-Update • Nov 07

MEDP: Below-Normal Bookings In 2025 Will Pressure Revenue Expansion

Analysts have raised their price target for Medpace Holdings from $456 to approximately $519, citing higher growth estimates and renewed confidence in the CRO sector's recovery. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets for Medpace, citing increased confidence in the recovery trajectory of the biotech sector and the broader contract research organization market.
Narrativ-Update • Oct 24

Future Sector Demand Shifts Will Influence Risk And Reward Dynamics

Analysts have raised their fair value estimate for Medpace Holdings to $456 from $428 per share. This change reflects updated optimism based on recent price target adjustments and expectations for stabilization in contract research organization demand trends.
Narrativ-Update • Oct 09

Tech-enabled Clinical Trials Will Balance Potential Risk And Reward

Analysts have raised Medpace Holdings’ fair value estimate modestly, from $423.64 to $428.00. Industry views reflect improved biotech funding and solid bookings, although some ongoing uncertainty in demand signals remains.
Narrativ-Update • Sep 04

Tech-enabled Clinical Trials Will Balance Potential Risk And Reward

As key metrics including the discount rate (7.16%) and net profit margin (16.85%) remained stable, the consensus analyst price target for Medpace Holdings was unchanged at $422.27. What's in the News Medpace completed a repurchase of 1,754,264 shares (5.89% of shares outstanding) for $518.54 million in Q2 2025, bringing the total buyback under its current program to 14.76% of shares outstanding and $1.27 billion since October 2022 (Key Developments).
Analyseartikel • Aug 11

Earnings Not Telling The Story For Medpace Holdings, Inc. (NASDAQ:MEDP) After Shares Rise 34%

Medpace Holdings, Inc. ( NASDAQ:MEDP ) shareholders have had their patience rewarded with a 34% share price jump in the...
Analyseartikel • Jul 24

Medpace Holdings, Inc. Beat Revenue Forecasts By 12%: Here's What Analysts Are Forecasting Next

As you might know, Medpace Holdings, Inc. ( NASDAQ:MEDP ) just kicked off its latest second-quarter results with some...
Analyseartikel • Jul 01

Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?

Medpace Holdings, Inc. ( NASDAQ:MEDP ), might not be a large cap stock, but it saw a double-digit share price rise of...
Analyseartikel • Jun 12

Is Medpace Holdings, Inc. (NASDAQ:MEDP) Trading At A 48% Discount?

Key Insights The projected fair value for Medpace Holdings is US$587 based on 2 Stage Free Cash Flow to Equity Medpace...
Seeking Alpha • Feb 06

Medpace: Impressive Revenue Growth, High ROE Values, And High Growth Potential

Summary Medpace has had an excellent financial performance. Its revenues increased by 495.26% between 2016Q2 and 2024Q3. Meanwhile, its current ROE is 54.08%. The company focused on small and mid-size companies. In this segment, the company has gained competitive advantages. Despite the fact that Medpace has received high backlog cancellations, the company is still a solid firm, and it grew by 9.81% between 2023 and 2024Q3 TTM. In the short term, the CRO market will face a difficult time, but the market outlook for the long term expects an improvement. Read the full article on Seeking Alpha
Seeking Alpha • Oct 26

Medpace: Buy The Short-Term Pain For Long-Term Gains

Summary Medpace Holdings' stock fell after Q3 earnings due to revenue growth concerns and a low book-to-bill ratio, but the long-term prospects remain strong. Medpace offers full-service clinical trial management, catering mainly to small biopharma companies lacking trial expertise, making it a stand-out player in the CRO market. Despite short-term revenue growth issues, Medpace's financials are impressive, with high profitability, no debt, and strong returns on capital, justifying a Buy rating. The stock is reasonably priced, trading below historical averages, and is poised for long-term growth, especially if biopharma funding rebounds as expected. Read the full article on Seeking Alpha
Seeking Alpha • Oct 16

Why Medpace Holdings Is A 'Better Mousetrap'

Summary Initiated a position in Medpace, increased investment after Q2 earnings miss; believe stock issues are temporary, presenting a buying opportunity. Medpace, a niche leader in CRO industry, operates under a full-service outsourcing model, serving small biotech companies with high-value, tailored solutions. Impressive financials: 20%+ revenue growth, 100%+ free cash flow conversion, 50%+ return on invested capital, large growth runway in a growing market. Stock price down 20% due to biotech R&D slowdown; long-term industry drivers intact, Medpace trading at an attractive valuation with superior growth prospects. Read the full article on Seeking Alpha
User avatar
Neues Narrativ • Aug 22

Temporary Setbacks Poised For A Swift Recovery And Strong Future Revenue Growth

Elevated project cancellations pose only a temporary risk, with potential for quick revenue and net new business awards recovery.
Seeking Alpha • Aug 20

Medpace: Continued Business Growth With Asymmetrical Payoff Opportunity

Summary Medpace stock is up 69% since my original buy rating, backed by strong profitability and cash flow generation. Q2 earnings show continued growth and backlog strength, with potential for further value creation above opportunities of equal risk. Forward estimates on conservative assumptions imply the intrinsic worth of the business is above $400/share. Read the full article on Seeking Alpha

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:MEDP - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20283,2056067437899
12/31/20272,90253362867212
12/31/20262,77149257261212
3/31/20262,678460711739N/A
12/31/20252,530451682713N/A
9/30/20252,358433677711N/A
6/30/20252,232418580614N/A
3/31/20252,157416541582N/A
12/31/20242,109404572609N/A
9/30/20242,071366536575N/A
6/30/20242,030340503540N/A
3/31/20241,963312473506N/A
12/31/20231,886283397433N/A
9/30/20231,782273378414N/A
6/30/20231,673268373408N/A
3/31/20231,563257385422N/A
12/31/20221,460245351388N/A
9/30/20221,374227286322N/A
6/30/20221,286209250286N/A
3/31/20221,213199221252N/A
12/31/20211,142181235263N/A
9/30/20211,094182271298N/A
6/30/20211,028175256285N/A
3/31/2021955159235267N/A
12/31/2020926145227259N/A
9/30/2020896124181210N/A
6/30/2020882107188215N/A
3/31/2020891110196217N/A
12/31/2019861100N/A202N/A
9/30/201982393N/A184N/A
6/30/201978688N/A173N/A
3/31/201974278N/A167N/A
12/31/201870573N/A157N/A
9/30/201861261N/A146N/A
6/30/201853152N/A132N/A
3/31/201845645N/A121N/A
12/31/201738639N/A97N/A
9/30/201738228N/A98N/A
6/30/201737923N/A101N/A
3/31/201737718N/A78N/A
12/31/201637113N/A92N/A
9/30/20163615N/A91N/A
6/30/20163480N/A80N/A
3/31/2016332-5N/A94N/A
12/31/2015320-9N/A86N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MEDPDas prognostizierte Gewinnwachstum (9.4% pro Jahr) liegt über der Sparquote (3.5%).

Ertrag vs. Markt: MEDPDie Erträge des Unternehmens (9.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (16.8% pro Jahr).

Hohe Wachstumserträge: MEDPDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: MEDPDie Einnahmen des Unternehmens (7.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.6% pro Jahr).

Hohe Wachstumseinnahmen: MEDPDie Einnahmen des Unternehmens (7.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MEDPDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (33%)

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/20 13:29
Aktienkurs zum Tagesende2026/05/20 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Medpace Holdings, Inc. wird von 20 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Eric ColdwellBaird
Luke SergottBarclays
Sean DodgeBMO Capital Markets Equity Research